NCT06747832Enrolling By Invitation1 期
A Single-center, Single-arm Clinical Study of the Efficacy and Safety of INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
Guangzhou Ruixin Biotechnological Co., LTD1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2024年12月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Number of Participants with Adverse Event (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v5.0
研究概览
简要总结
This is a clinical study on the use of iNK cells for the treatment of small cell lung cancer.
详细描述
Natural killer (NK) cells are lymphocytes of the innate immune system and could recognize and kill a wide range of cells in distress, particularly tumour cells and cells infected with viruses. Induced pluripotent setm cells(iPSCs) derived NK cells have better proliferative capacity and homogeneity than donor peripheral blood or umbilical cord blood derived NK cells. The investigators conduct this clinical study to evaluate the efficacy and safety of INK cells as maintenance therapy after chemoradiotherapy for small cell lung cancer and The purpose of investigators is to find new treatment option.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willingness to provide informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Age ≥18 years old and ≤ 75 years old at the time of signing the ICF
- •Have cytologically or histologically confirmed diagnosis for the patients with locally advanced unresectable or metastatic small cell lung cancer.
- •Have measurable disease as assessed by the investigator according to RECIST 1.
- •Have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) performance scale.
- •Have a life expectancy of ≥ 3 months.
- •Female participants: Women of childbearing potential (WOCBP) must use a highly effective form of contraception from the screening visit until at least 12 months after the final dose of iNK cells.
- •Male participants: Males must be sterile (biologically or surgically) or use a highly effective method of contraception from the screening visit until at least12 months after the final dose of iNK cells.
排除标准
- •Has evidence of insufficient organ function. 1.1 Has active or clinically significant cardiac disease including: 1.1.1 Severe heart rhythm or conduction abnormalities, corrected QT interval (QTc) ≥ 480 ms.
- •1.1.2 Complete left bundle branch block, second- or third-degree atrioventricular block.
- •1.1.3 Severe, uncontrolled cardiac arrhythmias requiring medication. 1.1.4 New York Heart Association (NYHA) class II or above congestive heart failure.
- •1.1.5 Left ventricular ejection fraction (LVEF) < 50% in color Doppler echocardiography.
- •1.1.6 History of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, severe pericardial disease, ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to recruitment.
- •1.2 Renal: SCR > 1.5 x ULN or calculated creatinine clearance (Cockcroft-Gault Formula) <60 mL/min.
- •1.3 Liver: 1.3.1 total bilirubin > 1.5 x ULN. 1.3.2 AST>2x ULN or ALT>2x ULN. AST/ALT can be as high as 5× ULN in liver metastases, but it cannot be accompanied by elevated bilirubin 1.4 lung:
- •> grade 1 dyspnea and oxygen saturation ≤ 91% in non oxygen breathing state. 1.5 Hematological: 1.5.1 Absolute neutrophil count (ANC) < 1.5 x 109/L. 1.5.2 Platelet count< 100 x 109/L. 1.5.3 Hemoglobin < 9.0g/dL. 1.5.4 International normalized ratio (INR) > 1.5 times ULN, and activated partial prothrombin time (APTT) > 1.5 times ULN;
- •At the time of screening, patients with symptomatic central nervous system (CNS) metastases (asymptomatic CNS metastases, or asymptomatic after local treatment and stable condition for 4 weeks can be enrolled).
- •Those with a history of central nervous system before screening, such as epilepsy, cerebral ischemia / hemorrhage, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, cerebral organic syndrome, mental disease or any autoimmune disease involving the central nervous system.
- •Those who stopped systemic hormone therapy for less than 72 hours before cell transfusion; But it is allowed to use a physiological substitute amount of hormone (such as prednisone < 10mg / D or equivalent).
- •Active systemic autoimmune disease is known before screening and is under treatment.
- •Those who meet any of the following conditions during screening: 6.8.1 Positive for hepatitis B surface antigen (HBsAg) and / or hepatitis B e antigen (HBeAg).
- •6.8.2 Hepatitis B e antibody (HBE AB) and / or hepatitis B core antibody (HBC AB) are positive, and the copy number of HBV-DNA is greater than the lower measurable limit.
- •6.8.3 Positive for hepatitis C antibody (HCV AB). 6.8.4 Positive anti Treponema pallidum antibody (TP AB). 6.8.5 HIV antibody test positive. 6.8.6 The copy number of EBV-DNA and cmv-dna is greater than the lower measurable limit.
- •Participated in other intervention clinical studies within 4 weeks before screening;
- •People who are allergic to human blood albumin.
- •People who are allergic to IL-
- •Patients who are judged by the investigator to be unsuitable for participating in this study.
研究组 & 干预措施
iNK Cell therapy group
Experimental
Intravenous infusion of iNK cells is given to the subject, 5*108 to 1*109 cells/dose, three doses per week, a total of 6 doses. And then 1*109 cells/dose, one doses every 4 weeks , a total of 5 doses.
干预措施: iNK cells (Drug)
结局指标
主要结局
Number of Participants with Adverse Event (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v5.0
时间窗: 12 months
Objective-response rate (ORR)
时间窗: 12 months
次要结局
- Progression Free Survival (PFS)(12 months)
- Duration of Response (DoR)(12 months)
- Overall Survival (OS)(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous LeukemiaAcute Myeloid Leukemia (AML)NCT06702098Guangzhou Ruixin Biotechnological Co., LTD10
Unknown
1 期
Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung CancerAdvanced Lung CancerNCT03751592Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd144
Unknown
1 期
Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid TumoursSolid TumoursNCT03415100The Third Affiliated Hospital of Guangzhou Medical University30
尚未招募
1 期
A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant AscitesGynecologic CancerNCT06415500Anhui Provincial Hospital9
招募中
1 期
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT06421701Second Affiliated Hospital, School of Medicine, Zhejiang University10